netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
  • CONTACT US
No announcement available or all announcement expired.
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
  • CONTACT US

NetScientific invests in PDS Biotechnology

Dec 15, 2014
-
News, PDS Biotechnology, RNS Announcements
RNS Number : 7136Z
NetScientific PLC
15 December 2014

 

NetScientific plc

(‘NetScientific’ or ‘the Group’) 

 

NetScientific Invests in Next Generation, Immunotherapeutics Company,
PDS Biotechnology

 

15 December 2014: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’).

 

PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious disease.  Its novel synthetic nanoparticle platform technology developed by PDS, Versamune®, activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system.

 

The Company’s lead product, PDS0101, is in phase I clinical trials in the US for HPV-related cancers.  PDS has licensed the Versamune® technology to Merck KGaA for use in two early stage cancer immunotherapy programmes. The company has also ongoing pre-clinical programmes for other cancers as well as pandemic influenza.

 

Farad Azima, CEO, “This is an exceptional opportunity for NetScientific. As we stated in our recent results, we have been evaluating opportunities in the therapeutic space. PDS Biotechnology is at the forefront of cancer immunotherapies and by investing in the company, represents our entry into next generation therapeutics.”

 

Sir Richard Sykes, Chairman added, “The groundbreaking work of PDS in developing immunotherapeutics has the potential to transform treatments for a wide range of cancers and infectious diseases. We are delighted to be supporting the Company through its next stage of development.”

 

-Ends-

 

 

Notes to Editors

 

About NetScientific

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.NetScientific.net

 

About PDS

 

PDS Biotechnology is an immunotherapeutics company developing its powerful nanoparticle technology, called Versamune®, as a novel cancer therapy platform with outstanding potential in directing the immune system to recognise and fight disease. The Company is developing a range of applications in cancer and infectious disease and its first lead compound is in phase I clinical trials.  The company is based in New Jersey, US. For specific information on PDS please contact Michael King at mking@pdsbiotech.com.  http://www.pdsbiotech.com

 

 

Contact Details

 

NetScientific plc

Farad Azima

Peter Thoms

Tel: +44 (0) 20 3290 8877

Liberum (NOMAD and Broker)

Chris Bowman / Christopher Britton /
Thomas Bective

Tel: +44 (0)20 3100 2000

Instinctif Partners

Melanie Toyne-Sewell / Tim Watson

Tel: +44 (0) 20 7457 2020

Email: netscientific@instinctif.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCEAAALFLNLFAF

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
NetScientific invests in DName-iT
NEXT POST →
NetScientific enters into alliance with Healthbox

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
copyright
Terms of Use
NetScientific invests in PDS Biotechnology - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.